Raf/MEK/ERK signaling is activated in more than 50% of HCC [39], whereas PI3K/AKT/mTOR signaling is activated in about 40-50% of HCC [23, 35, 40]. The gene discussed is MAP2K7; the disease is hepatocellular carcinoma.